AI-Based sTIL analysis expands identification of HER2+ BC patients benefiting from pertuzumab
Dr Llewelyn talks to ecancer at the PETIC centre in Wales about the work done at the centre creating radiopharmaceuticals.
Discussing the process of how they're created, processed for human consumption and the biology of how the tracers work.
AI-Based sTIL analysis expands identification of HER2+ BC patients benefiting from pertuzumab
Predicting tumour mutations from pathology images may help increase personalised medicine utilisation
Cancer mutation prediction using artificial intelligence
Best practice in HRRm testing in patients with metastatic prostate cancer
Bone disease evaluation of newly diagnosed MM with combined use of 18F-FDG PET/CT and whole-body diffusion weighted MRI
Multiple myeloma in a resource constrained setting
SABCS 2023: Latest breast cancer diagnostics guidelines
Genomic testing: Awareness and effective communication between healthcare professionals and patients
Choosing Wisely in radiology Tanzania